Talton v. Arnall Golden Gregory, LLP

622 S.E.2d 589, 276 Ga. App. 21, 2005 Ga. App. LEXIS 1076
CourtCourt of Appeals of Georgia
DecidedSeptember 29, 2005
DocketA05A1190
StatusPublished
Cited by11 cases

This text of 622 S.E.2d 589 (Talton v. Arnall Golden Gregory, LLP) is published on Counsel Stack Legal Research, covering Court of Appeals of Georgia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Talton v. Arnall Golden Gregory, LLP, 622 S.E.2d 589, 276 Ga. App. 21, 2005 Ga. App. LEXIS 1076 (Ga. Ct. App. 2005).

Opinion

Ellington, Judge.

Timothy C. Taitón appeals from the trial court’s dismissal of his negligence action against William H. Kitchens and the law firm of Arnall Golden Gregory, LLP. Finding no error, we affirm.

“A motion to dismiss may be granted only when the complaint establishes that the plaintiff is not entitled to relief under any facts that could be proved. We review the trial court’s ruling de novo.” (Citations omitted.) Cook v. Regional Communications, 244 Ga. App. 869, 870 (539 SE2d 171) (2000). The complaint at issue shows the following: CryoLife, Inc. is a corporation which purchased human cadaver tissue from another company, then processed, packaged, and distributed the tissue to hospitals for use in implants and other surgeries. Prior to June 2001, CryoLife was aware that some of the cadaver tissue it had processed was contaminated with Clostridium bacteria. Even with this knowledge, CryoLife failed to properly test or treat the cadaver tissue before distributing the tissue to hospitals, and such failure violated industry standards.

Defendants Kitchens and his employer, Arnall Golden Gregory, LLP (collectively, “AGG”), were CryoLife’s attorneys. Prior to June 2001, AGG consulted with CryoLife about the cadaver tissue and was aware of CryoLife’s procedures for testing and treating the cadaver tissue. AGG recommended to CryoLife that the corporation attach *22 warning labels to the cadaver tissue packages stating that the tissue was not sterile and advising physicians to prescribe prophylactic antibiotics. At some point after AGG made that recommendation, but before June 2001, CryoLife shipped the tissue to hospitals in packages that contained warning labels which stated the tissue had been tested for infectious disease. The labels also said the tissue had been

treated with antimicrobials to reduce the number of organisms that may have been present at the time of procurement, and subsequently, a portion of this tissue was tested and found to be free from detectable levels of bacterial and fungal microorganisms. Although this tissue has been tested, there is no assurance that this tissue is free from all infectious ■ diseases or microbial contamination.

Each package also contained a “Certificate of Assurance” which stated that “This allograft was aseptically processed by CryoLife’s proprietary process. The finished product conforms to CryoLife’s strict and exacting microbiology and quality standards.” It is undisputed that neither the warning label nor the Certificate of Assurance referred in any way to Kitchens or AGG.

On June 27, 2001, Taitón had outpatient knee surgery involving an allograft medial meniscus implant in his right knee. The physician performing the allograft used cadaver tissue that had been provided to the hospital by CryoLife. Prior to Talton’s surgery, CryoLife had actual knowledge that the donor of the cadaver tissue used in the surgery was infected with Clostridium bacteria, but did not notify the hospital or Talton’s physician. It is undisputed that Taitón never saw the warning label on the tissue package prior to his surgery. Taitón developed a severe post-operative infection in his knee which required additional surgeries and caused other serious injuries.

On July 25, 2003, Taitón sued CryoLife and its corporate officers for strict liability, negligence, and professional negligence. 1 The complaint alleged that CryoLife failed to properly process the cadaver tissue and failed to adequately warn patients, physicians, and hospitals of the risks of implanting the tissue. In Count 3 of the complaint, Taitón also sued CryoLife’s lawyers, Kitchens and AGG, for common law negligence. 2 Taitón alleged that AGG acted negligently when it recommended and prepared an inadequate warning label and that, when it did so, AGG knew that third parties, including hospitals, physicians, and patients, would rely on the warning label.

*23 AGG answered and filed a motion to dismiss Count 3 of the complaint pursuant to OCGA § 9-11-12 (b) (6). In its answer and at the motion hearing, AGG contended that it had no duty as a matter of law to warn nonclients, such as patients receiving the cadaver tissue during surgery, of risks associated with the tissue. It also noted that, when a medical device can only be prescribed or inserted by a physician, the physician is solely responsible for informing the patient of the risks of using the device. It is undisputed that CryoLife never distributed the cadaver tissue directly to patients and that hospitals or physicians removed the tissue from the packaging prior to or during surgery, and AGG contended that patients never had the opportunity to review or rely upon the warning label. In addition, AGG argued that it provided legal advice regarding the warning label to its client, CryoLife, and that such advice was confidential and intended only for CryoLife’s consideration and use. According to AGG, because patients never actually saw the warning label, Taitón could not show that AGG was actually aware that patients such as Taitón would rely on AGG’s confidential legal advice to CryoLife regarding the label. Further, AGG argued that it had no control as to whether CryoLife followed its advice, noting that CryoLife made the final decision on whether to accept AGG’s legal advice and what information, if any, to include in the warning label. AGG asserted that CryoLife was therefore solely responsible for the adequacy of the warning labels. In response, Taitón contended that, by advising CryoLife on the language for the warning labels, AGG had undertaken a duty to warn third parties of the risks and, therefore, was responsible for the harm resulting from the inadequate warning. The trial court granted AGG’s motion to dismiss, and Taitón appeals.

1. Taitón contends the trial court erred in finding as a matter of law that AGG owed no duty to adequately warn him of the material risks of using the cadaver tissue. In order to maintain a cause of action for negligence, a plaintiff must be able to prove that the defendant owed a legally cognizable duty to the plaintiff to conform to a certain standard of conduct, the defendant breached this duty, and the breach damaged the plaintiff. Martha H. West Trust v. Market Value of Atlanta, 262 Ga. App. 90, 91 (1) (584 SE2d 688) (2003). In this case, it is undisputed that Taitón was never a client of AGG and that there was no privity between the parties that might have created a duty owed by AGG to Taitón. Therefore, Taitón must show that AGG owed him a duty under some other legal theory. Id.

(a) Taitón argues that AGG’s duty to him arose under the Restatement of Torts 2d, § 552 (1977). 3 The Supreme Court of Georgia *24 adopted Section 552 of the Restatement in Robert & Co. Assoc. v. Rhodes-Haverty Partnership, 250 Ga. 680, 681-682 (300 SE2d 503) (1983), a case in which the Court considered whether an engineer could be liable to a limited class of third parties when it was foreseeable that the third parties would rely on the engineer’s report. The Court adopted the following rule:

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
622 S.E.2d 589, 276 Ga. App. 21, 2005 Ga. App. LEXIS 1076, Counsel Stack Legal Research, https://law.counselstack.com/opinion/talton-v-arnall-golden-gregory-llp-gactapp-2005.